In summary, this study demonstrated that pharmacologic inhibition of the BMP signaling pathway prevented the development of hepatic steatosis in a murine model of NAFLD likely via SMAD-dependent regulation of Dgat2. The gene discussed is DGAT2; the disease is metabolic dysfunction-associated steatotic liver disease.